重组人Ⅱ型肿瘤坏死因子受体-抗体治疗类风湿关节炎60例临床观察  

Recombinant Human Tumor Necrosis Factor Receptor type Ⅱ-antibody Treatment of Rheumatoid Arthritis Clinical Observation in 60 cases

作　　者：黄志勇[1] 谭志明[1] 庄宇[1] 

机构地区：[1]广东省惠州市中心人民医院,广东惠州516001

出　　处：《哈尔滨医药》2010年第4期38-39,共2页Harbin Medical Journal

摘　　要：目的探讨应用重组人Ⅱ型肿瘤坏死因子受体-抗体治疗类风湿关节炎临床效果。方法 2008年1月-2009年12月收治120例类风湿关节炎患者随机分为观察组和对照组各60例。对照组选用甲氨蝶呤,口服,每周用10mg,3周后增到15mg,每周1次,以后维持6-12周;观察组应用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白皮下每次注射25mg,每周注射2次,共注射12周。结果观察组显效33例,有效18例,无效9例,总有效率为85.0%,早期疗效反应,出现1周后反应明显,明显疗效反应发生在1个疗程结束前后;对照组显效30例,有效12例,无效18例,总有效率为70.0%,低于对照组（P〈0.05）,且起效慢。两组观察组和对照组中总的不良反应发生率分别是43.3%和41.7%（P〉0.05）,未发生结核病和恶性肿瘤,无死亡病例和严重不良事件。结论重组人Ⅱ型肿瘤坏死因子受体-抗体能有效改善类风湿关节炎患者的症状,比甲氨蝶呤起效快、效果更明显,值得临床应用。Objective To investigate the use of recombinant human tumor necrosis factor receptor type Ⅱ-antibody rheumatoid arthritis clinical effects.Methods in January 2008-2,009 12 120 cases were treated in patients with rheumatoid arthritis were randomly divided into two groups and the control group,with 60 cases in the control group used methotrexate,oral,once a week with 10mg,3 weeks increased to 15mg,per Week 1,after the maintenance of 6-12 weeks;observation group Ⅱ type recombinant human tumor necrosis factor receptor-antibody fusion protein injected subcutaneously every 25mg,2 times a week and a total injection l2 weeks.Results observed 33 cases were excellent,effective,18 were effective in 9 cases,total effective rate was 85.0%,the early effect of reaction,reaction occurs significantly after 1 week,significant effects of reaction occurred in a before and after the end of treatment;the control group that were 30 patients effective in 12 cases,18 cases ineffective,the total effective rate was 70.0%,lower than the control group（P〈0.05）,and the slow onset.Two observation group and control group the total incidence of adverse events were 43.3 and 41.7%（P〉0.05）,tuberculosis and malignant tumors did not occur,no deaths and serious adverse events.Conclusion of recombinant human tumor necrosis factor receptor type Ⅱ-antibodies can effectively improve the symptoms of rheumatoid arthritis patients than methotrexate rapid onset of effect was more obvious,is worthy of clinical application.

关 键 词：重组人Ⅱ型肿瘤坏死因子受体-抗体 甲氨蝶呤 类风湿关节炎临床 

分 类 号：R593.22[医药卫生—内科学]